Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21296192rdf:typepubmed:Citationlld:pubmed
pubmed-article:21296192lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:21296192lifeskim:mentionsumls-concept:C0019740lld:lifeskim
pubmed-article:21296192lifeskim:mentionsumls-concept:C0949691lld:lifeskim
pubmed-article:21296192pubmed:issue8lld:pubmed
pubmed-article:21296192pubmed:dateCreated2011-6-3lld:pubmed
pubmed-article:21296192pubmed:abstractTextHLA-B27 (Human Leukocyte Antigen-B27) accounts approximately for the one third of the overall genetic susceptibility to spondylorthropathies (SpAs). Up to 70 HLA-B27 subtypes have been reported all over the world with a decreasing north-south gradient of its frequency, which is reverse to that of endemic malaria. In an attempt to explain the possible role of HLA-B27 in SpAs pathogenesis, several theories have been suggested [1. Arthritogenic peptide, 2. Misfolding, 3. Cell surface HLA-B27 homodimers, 4. ?2m (?2-microglobulin) deposition, 5. ?2m-free/peptide free heavy chains of HLA-I, 6. Enhanced survival of some microbes in HLA-B27 cells, 7. ERAP1/ERAP2 (endoplasmic reticulum aminopeptidases 1 and 2) and Tapasin function, 8. ?2m over-expression] each of which contributes up to a point to our understanding of HLA-B27 subtypes' role in SpAs manifestation. However, reviewing all the suggested hypotheses it seems logical to pass from a puzzle of distinct hypotheses to a global theory. This review summarizes the current knowledge of HLA-B27 aiming to understand its potential use in clinical practice of SpAs diagnosis and to direct its future studies.lld:pubmed
pubmed-article:21296192pubmed:languageenglld:pubmed
pubmed-article:21296192pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21296192pubmed:citationSubsetIMlld:pubmed
pubmed-article:21296192pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21296192pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21296192pubmed:statusMEDLINElld:pubmed
pubmed-article:21296192pubmed:monthJunlld:pubmed
pubmed-article:21296192pubmed:issn1873-0183lld:pubmed
pubmed-article:21296192pubmed:authorpubmed-author:VoulgariParas...lld:pubmed
pubmed-article:21296192pubmed:authorpubmed-author:DrososAlexand...lld:pubmed
pubmed-article:21296192pubmed:authorpubmed-author:Chatzikyriaki...lld:pubmed
pubmed-article:21296192pubmed:copyrightInfoCopyright © 2011 Elsevier B.V. All rights reserved.lld:pubmed
pubmed-article:21296192pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21296192pubmed:volume10lld:pubmed
pubmed-article:21296192pubmed:ownerNLMlld:pubmed
pubmed-article:21296192pubmed:authorsCompleteYlld:pubmed
pubmed-article:21296192pubmed:pagination464-8lld:pubmed
pubmed-article:21296192pubmed:meshHeadingpubmed-meshheading:21296192...lld:pubmed
pubmed-article:21296192pubmed:meshHeadingpubmed-meshheading:21296192...lld:pubmed
pubmed-article:21296192pubmed:meshHeadingpubmed-meshheading:21296192...lld:pubmed
pubmed-article:21296192pubmed:meshHeadingpubmed-meshheading:21296192...lld:pubmed
pubmed-article:21296192pubmed:meshHeadingpubmed-meshheading:21296192...lld:pubmed
pubmed-article:21296192pubmed:meshHeadingpubmed-meshheading:21296192...lld:pubmed
pubmed-article:21296192pubmed:meshHeadingpubmed-meshheading:21296192...lld:pubmed
pubmed-article:21296192pubmed:meshHeadingpubmed-meshheading:21296192...lld:pubmed
pubmed-article:21296192pubmed:year2011lld:pubmed
pubmed-article:21296192pubmed:articleTitleWhat is the role of HLA-B27 in spondyloarthropathies?lld:pubmed
pubmed-article:21296192pubmed:affiliationRheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110 Ioannina, Greece.lld:pubmed
pubmed-article:21296192pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21296192pubmed:publicationTypeReviewlld:pubmed